Q-omics provides the consensus-scored LIN7C profile across patient tissues and cancer cell-line models. LIN7C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIN7C is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, LIN7C protein abundance shows 22,110 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, LUSC, and LUAD as cancer lineages where LIN7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN7C survival associations across molecular data types. LIN7C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN7C RNA expression–survival associations across cancer types. High LIN7C expression shows unfavorable associations in UCS, ACC, LGG and KIRP, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIN7C RNA expression.
This table summarizes LIN7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIN7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN7C shows lower tumor expression in THCA, READ, BLCA and KICH and higher tumor expression in LUSC and STAD. The LUSC box plot shows higher LIN7C RNA expression in tumor versus normal tissue (log2 FC = +0.419, t-test p < 0.001).
This table shows molecular features associated with LIN7C in patient tissues and cancer cell lines. In patient samples, LIN7C shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN7C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
